References

1. Lietava J. Medicinal plants in a Middle Paleolithic grave Shanidar IV? J Ethnopharmacol 1992;35(3):263-266.

2. Kasahara Y, Hikino H, Tsurufuji S, Watanabe M, Ohuchi K. Antiinflammatory actions of ephedrines in acute inflammations. Planta Med 1985;(4):325-331.

3. Grinspoon L, Hedblom P, eds. The speed culture: amphetamine use and abuse in America. Cambridge: Harvard University Press, 1975.

4. al-Khalil S, Alkofahi A, el-Eisawi D, al-Shibib A. Transtorine, a new quinoline alkaloid from Ephedra transitoria. J Nat Prod 1998;61(2):262-263.

5. Holmstedt B. Historical perspective and future of ethnopharmacology. J Ethnopharmacol 1991;32(1-3):7-24.

6. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-248.

7. Deverall RLG. Red China's dirty drug war; the story of the opium, heroin, morphine and philopon traffic. Tokyo, 1954.

8. Dewick PM, ed. Medicinal natural products: a biosynthetic approach. New York: Wiley, 1997.

9. Yap JC, Critchley LA, Yu SC, Calcroft RM, Derrick JL. A comparison of three fluid-vasopressor regimens used to prevent hypotension during subarachnoid anaesthesia in the elderly. Anaesth Intensive Care 1998;26(5):497-502.

10. Pomerantz B, O'Rourke R. The Stokes-Adams syndrome. Am J Med 1969;46(6):941-960.

11. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes 1998;106(Suppl 2):29-34.

12. Ramsey JJ, Colman RJ, Swick AG, Kemnitz JW. Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. Am J Clin Nutr 1998;68(1):42-51.

13. Greenway F, Herber D, Raum W, Herber D, Morales S. Double-blind, randomized, placebo controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res 1999;7(4):370-378.

14. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, doubleblind trial. Int J Obes Relat Metab Disord 2001;25(3):316-324.

15. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002;26(5):593-604.

16. Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. Sports Med 1997;24(6):366-384.

17. Bell DG, Jacobs I, McLellan TM, Zamecnik J. Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect. Aviat Space Environ Med 2000;71(4):415-419.

18. Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. Med Sci Sports Exerc 2001;33(8):1399-1403.

19. Bell DG, McLellan TM, Sabiston CM. Effect of ingesting caffeine and ephedrine on 10-km run performance. Med Sci Sports Exerc 2002;34(2):344-349.

20. Namba T, Kubo M, Kanai Y, Namba K, Nishimura H, Qazilbash NA. Pharmacog-nostical studies of Ephedra plants Part I—The comparative histological studies on

Ephedra rhizomes from Pakistan and Afghanistan and Chinese crude drugs "Ma-Hung-Gen". Planta Med 1976;29(3):216-225.

21. Sagara K, Oshima T, Misaki T. A simultaneous determination of norephedrine, pseudoephedrine, ephedrine and methylephedrine in Ephedrae Herba and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. Chem Pharm Bull (Tokyo) 1983;31(7):2359-2365.

22. Zhang JS, Tian Z, Lou ZC. [Quality evaluation of twelve species of Chinese Ephedra (ma huang)]. Yao Hsueh Hsueh Pao 1989;24(11):865-871.

23. Anonymous. Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule. Fed Regist 2002;67(60):14,853-14,862.

24. Gurley BJ, Gardner SF, White LM, Wang PL. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther Drug Monit 1998;20(4):439-445.

25. Haller CA, Jacob P III, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther 2002;71(6):421-432.

26. Webb AA, Shipton EA. Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for Caesarean section. Can J Anaesth 1998;45(4):367-369.

27. Neve KA, Molinoff PB. Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. Am J Cardiol 1986;57(12):17F-22F.

28. Williams BR, Barber R, Clark RB. Kinetic analysis of agonist-induced down regulation of the beta(2)-adrenergic receptor in BEAS-2B cells reveals high- and low-affinity components. Mol Pharmacol 2000;58(2):421-30.

29. Saupe KW, Smith CA, Henderson KS, Dempsey JA. Diastolic time: an important determinant of regional arterial blood flow. Am J Physiol 1995;269(3 Pt 2):H973-979.

30. Muittari A, Mattila MJ, Tiitinen H. The combined action of broncholytic agents in asthmatic patients: orciprenaline, isoprenaline, and ephedrine. Ann Med Intern Fenn 1968;57(1):31-35.

31. Muittari A, Mattila MJ, Patiala J. Bronchodilator action of drug combinations in asthmatic patients: decloxizine, orciprenaline, and ephedrine. Ann Allergy 1969;27(6):274-279.

32. Muittari A, Mattila MJ. Bronchodilator action of drug combinations in asthmatic patients. Ephedrine, theophylline and tranquilizing drugs. Curr Ther Res Clin Exp 1971;13(6):374-385.

33. Dulfano MJ, Glass P. Evaluation of a new B 2 adrenergic receptor stimulant, terbutaline, in bronchial asthma. II. Oral comparison with ephedrine. Curr Ther Res Clin Exp 1973;15(4):150-157.

34. Kerr A, Gebbie T. Comparison of orciprenaline, ephedrine and methoxyphenamine as oral bronchodilators. N Z Med J 1973;77(492):320-322.

35. Weinberger MM, Bronsky EA. Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children. J Pediatr 1974;84(3):421-427.

36. Bierman CW, Pierson WE, Shapiro GG. Exercise-induced asthma. Pharmacological assessment of single drugs and drug combinations. JAMA 1975;234(3):295-298.

37. Bierman CW, Pierson WE, Shapiro GG. The pharmacological assessment of single drugs and drug combinations in exercise-induced asthma. Pediatrics 1975;56(5 Pt-2 Suppl):919-922.

38. Bye C, Hill HM, Hughes DT, Peck AW. A comparison of plasma levels of L(+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. Eur J Clin Pharmacol 1975;8(1):47-53.

39. Chervinsky P, Chervinsky G. Metaproterenol tablets: their duration of effect by comparison with ephedrine. Curr Ther Res Clin Exp 1975;17(6):507-518.

40. Geumei A, Miller WF, Paez PN, Gast LR. Evaluation of a new oral beta2 adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology 1975;13(3):201-211.

41. Nelson HS, Black JW, Branch LB, et al. Subsensitivity to epinephrine following the administration of epinephrine and ephedrine to normal individuals. J Allergy Clin Immunol 1975;55(5):299-309.

42. Tashkin DP, Meth R, Simmons DH, Lee YE. Double-blind comparison of acute bronchial and cardiovascular effects of oral terbutaline and ephedrine. Chest 1975;68(2):155-161.

43. Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ. Interaction of ephedrine and theophylline. Clin Pharmacol Ther 1975;17(5):585-592.

44. Blumberg MZ, Tinkelman DG, Ginchansky EJ, Blumberg BS, Taylor JC, Avner SE. Terbutaline and ephedrine in asthmatic children. Pediatrics 1977;60(1):14-19.

45. Simi WW, Miller WC. Clinical investigation of fenoterol, a new bronchodilator, in asthma. J Allergy Clin Immunol 1977;59(2):178-181.

46. Tinkelman DG, Avner SE. Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects. JAMA 1977;237(6):553-557.

47. Tinkelman DG, Avner SE. Assessing bronchodilator responsiveness. J Allergy Clin Immunol 1977;59(2):109-114.

48. Bush RK, Smith AM, Welling PG, Alcala JC, Lee TP. A comparison of a theophyl-line-ephedrine combination with terbutaline. Ann Allergy 1978;41(1):13-17.

49. Chervinsky P. The development of drug tolerance during long-term beta2 agonist bronchodilator therapy. Chest 1978;73(6 Suppl):1001-1002.

50. Cohen BM. The cardiorespiratory effects of oral terbutaline and an ephedrine-theophylline-phenobarbital combination: comparison in patients with chronic obstructive ventilatory disorders. Ann Allergy 1978;40(4):233-239.

51. Eggleston PA, and McMahan S. A. The effects of fenoterol, ephedrine and placebo on exercise-induced asthma. Chest 1978;73(6 Suppl):1006-1008.

52. Falliers CJ. Controlled assessment of beta2 adrenergic therapy for childhood asthma. Chest 1978;73(6 Suppl):1008-1010.

53. Falliers CJ, Cato AE, Harris JR. Controlled assessment of oral bronchodilators for asthmatic children. J Int Med Res 1978;6(4):326-336.

54. Miller WC. Long-term beta2 bronchodilator therapy and the question of tolerance. Chest 1978;73(6 Suppl):1000-1001.

55. Stenius B, Haahtela T, Poppius H. Controlled comparison of Nuelin, Theodrox and Marax in asthmatic out-patients. Eur J Clin Pharmacol 1978;13(3):179-183.

56. VanArsdelPP Jr, Schaffrin RM, Rosenblatt J, Sprenkle AC, Altman LC. Evaluation of oral fenoterol in chronic asthmatic patients. Chest 1978;73(6 Suppl):997-998.

57. Banner AS, Sunderrajan EV, Agarwal MK, Addington WW. Arrhythmogenic effects of orally administered bronchodilators. Arch Intern Med 1979;139(4):434-437.

58. James TD, Lyons HA. A comparative study of bronchodilator effects of carbuterol and ephedrine. JAMA 1979;241(7):704-705.

59. Muittari A, Mattila MJ. Objective and subjective assessment of ephedrine combinations in asthmatic outpatients. Ann Clin Res 1979;11(3):87-89.

60. Pierson DJ, Hudson LD, Stark K, Hedgecock M. Cardiopulmonary effects of terbutaline and a bronchodilator combination in chronic obstructive pulmonary disease. Chest 1980;77(2):176-182.

61. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrener-gic receptor subtypes. Biochem Pharmacol 1999;58(5):807-810.

62. Astrup A. Thermogenic drugs as a strategy for treatment of obesity. Endocrine 2000;13(2):207-212.

63. Bray GA. Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S8-S17.

64. Cheng JT, Liu IM, Yen ST, Juang SW, Liu TP, Chan P. Stimulatory effect of D-ephedrine on beta3 adrenoceptors in adipose tissue of rats. Auton Neurosci 2001;88(1-2):1-5.

65. Castleden CM, Duffin HM, Briggs RS, Ogden BM. Clinical and urodynamic effects of ephedrine in elderly incontinent patients. J Urol 1982;128(6):1250-1252.

66. Kadar N, Nelson JH Jr. Treatment of urinary incontinence after radical hysterectomy. Obstet Gynecol 1984;64(3):400-405.

67. Alberts P, Bergstrom PA, Fredrickson MG. Characterisation of the functional alpha-adrenoceptor subtype in the isolated female pig urethra. Eur J Pharmacol 1999;371(1):31-38.

68. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord 1992;16(4):269-277.

69. Kanfer IR, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993;13(6 Pt 2):116S-128S; discussion 143S-146S.

70. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacoki-netics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol 1997;37(2):116-122.

71. Kuntzman RG, Tsai I, Brand L, Mark LC. The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. Clin Pharmacol Ther 1971;12(1):62-67.

72. Dickerson J, Perrier D, Mayersohn M, Bressler R. Dose tolerance and pharmacokinetic studies of L(+) pseudoephedrine capsules in man. Eur J Clin Pharmacol 1978;14:239-259.

73. Vanakoski J, Seppala T. Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics. Clin Pharmacokinet 1998;34(4):311-322.

74. Wilkinson G, Beckett A. Absorption, metabolism and excretion of the ephedrine in man. II. J Pharm Sci 1968;57:1933-1938.

75. Kunsman GW, Jones R, Levine B, Smith ML. Methylephedrine concentrations in blood and urine specimens. J Anal Toxicol 1998;22(4):310-313.

76. Tokunaga I, Takeichi S, Kujime T, Maeiwa M. Electroencephalographical analysis of acute drug intoxication—SS Bron solution-W. Arukoru Kenkyuto Yakubutsu Ison 1989;24(6):471-479.

77. Ishigooka J, Yoshida Y, Murasaki M. Abuse of "BRON": a Japanese OTC cough suppressant solution containing methylephedrine, codeine, caffeine and chlorpheniramine. Prog Neuropsychopharmacol Biol Psychiatry 1991;15(4):513-521.

78. Levine B, Caplan YH, Kauffman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986;10(5):209-210.

79. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343(25):1833-1838.

79a. Haller CA and Benowitz NL. Dietary supplements containing ephedra alkaloids, correspondence. N Engl J Med 2000;344(April 5):1095-1097.

80. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77(1):12-16.

81. Kingston R, Blumenthal M. A rational perspective on adverse events reports on herbs: misinterpretation of adverse reactions tabulated in the TESS Annual Report of the American Association of Poison Control Centers as they relate to ephedra dietary supplements. HerbalGram 2003;60:48-53.

82. Pentel P. Toxicity of over-the-counter stimulants. JAMA 1984;252(14):1898-1903.

83. Stoessl AJ, Young GB, Feasby TE. Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. Stroke 1985;16(4):734-736.

84. Roberge RJ, Hirani KH, Rowland PL III, Berkeley R, Krenzelok EP. Dextromethorphan- and pseudoephedrine-induced agitated psychosis and ataxia: case report. J Emerg Med 1999;17(2):285-288.

85. Wilson H, Woods D. Pseudoephedrine causing mania-like symptoms. N Z Med J 2002;115(1148):86.

86. Johnson DA, Etter HS, Reeves DM. Stroke and phenylpropanolamine use. Lancet 1983;2(8356):970.

87. Glick R, Hoying J, Cerullo L, Perlman S. Phenylpropanolamine: an over-the-counter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review. Neurosurgery 1987;20(6):969-974.

88. Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. Am J Med 1989;86(4):427-432.

89. Thomas SH, Clark KL, Allen R, Smith SE. A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies. Br J Clin Pharmacol 1991;32(6):705-711.

90. Ryu SJ, Lin SK. Cerebral arteritis associated with oral use of phenylpropanolamine: report of a case. J Formos Med Assoc 1995;94(1-2):53-55.

91. Tapia J. [Cerebral hemorrhage associated with the use of phenylpropanolamine. Clinical cases]. Rev Med Chil 1996;124(12):1499-1503.

92. Chung YT, Hung DZ, Hsu CP, Yang DY, Wu TC. Intracerebral hemorrhage in a young woman with arteriovenous malformation after taking diet control pills containing phenylpropanolamine: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61(7):432-435.

93. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):1826-1832.

94. Vahedi K, Domigo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. J Neurol Neurosurg Psychiatry 2000;68(1):112-113.

95. du Boisgueheneuc F, Lannuzel A, Caparros-Lefebvre D, De Broucker T. [Cerebral infarction in a patient consuming MaHuang extract and guarana]. Presse Med 2001;30(4):166-167.

96. Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. Neurology 1993;43(7):1313-1316.

97. Loizou LA, Hamilton JG, Tsementzis SA. Intracranial haemorrhage in association with pseudoephedrine overdose. J Neurol Neurosurg Psychiatry 1982;45(5):471-472.

98. LeBayon A, Castelnovo G, Briere C, Labauge P. [Cerebromeningeal hemorrhage after voluntary overdose of pseudoephedrine]. Presse Med 2000;29(31):1702.

99. Mourand I, Ducrocq X, Lacour JC, Taillandier L, Anxionnat R, Weber M. Acute reversible cerebral arteritis associated with parenteral ephedrine use. Cerebrovasc Dis 1999;9(6):355-357.

100. Jovanovic Z. [Risk factors for stroke in young people]. Srp Arh Celok Lek 1996;124(9-10):232-235.

101. Herridge CF, a'Brook MF. Ephedrine psychosis. Br Med J 1968;2(598):160.

102. Roxanas MG, Spalding J. Ephedrine abuse psychosis. Med J Aust 1977;2(19):639-640.

103. Shufman NE, Witztum E, Vass A. [Ephedrine psychosis]. Harefuah 1994;127(5-6):166-168, 215.

104. Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. BMJ 1996;313(7059):756.

105. Tormey WP, Bruzzi A. Acute psychosis due to the interaction of legal com-pounds—ephedra alkaloids in "vigueur fit" tablets, caffeine in "red bull" and alcohol. Med Sci Law 2001;41(4):331-336.

106. Kalix P. The pharmacology of psychoactive alkaloids from ephedra and catha. J Ethnopharmacol 1991;32(1-3):201-208.

107. Bories H. [Kidney stones]. Infirm Fr 1976;(179):13-18.

108. Schweisheimer W. [Kidney stones]. Krankenpflege (Frankf) 1976;30(6):194-195.

109. Blau JJ. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. J Urol 1998;160(3 Pt 1):825.

110. Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis 1998;32(1):153-159.

111. Assimos DG, Langenstroer P, Leinbach RF, Mandel NS, Stern JM, Holmes RP. Guaifenesin- and ephedrine-induced stones. J Endourol 1999;13(9):665-667.

112. Glidden RS, DiBona FJ. Urinary retention associated with ephedrine. J Pediatr 1977;90(6):1013-1014.

113. Lindberg AW. [Urinary retention caused by Elsinore pills]. Ugeskr Laeger 1988;150(35):2086-2087.

114. Lyon CC, Turney JH. Pseudoephedrine toxicity in renal failure. Br J Clin Pract 1996;50(7):396-397.

115. Brater DC, Kaojarern S, Benet LZ, et al. Renal excretion of pseudoephedrine. Clin Pharmacol Ther 1980;28(5):690-694.

116. Karch SB, Stephens B, Ho CH. Relating cocaine blood concentrations to toxic-ity—an autopsy study of 99 cases. J Forensic Sci 1998;43(1):41-45.

117. Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 1999;44(2):359-368.

118. To LB, Sangster JF, Rampling D, Cammens I. Ephedrine-induced cardiomyopathy. Med J Aust 1980;2(1):35-36.

119. Gaultieri J. Cardiomyopathy in a heavy ephedrine abuser. J Tox Clin Tox 1996;34:581-582.

120. Cockings JG, Brown M. Ephedrine abuse causing acute myocardial infarction. Med J Aust 1997;167(4):199-200.

121. Menegakis NE, Amstey MS. Case report of myocardial infarction in labor. Am J Obstet Gynecol 1991;165(5 Pt 1):1383-1384.

122. Wiener I, Tilkian AG, Palazzolo M. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseu-doephedrine ingestion. Cathet Cardiovasc Diagn 1990;20(1):51-53.

123. Derreza H, Fine MD, Sadaniantz A. Acute myocardial infarction after use of pseudoephedrine for sinus congestion. J Am Board Fam Pract 1997;10(6):436-438.

124. Hirabayashi Y, Saitoh K, Fukuda H, Mitsuhata H, Shimizu R. Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. Anesthesiology 1996;84(1):221-224.

125. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999;37(4):485-489.

126. Anastasio GD, Harston PR. Fetal tachycardia associated with maternal use of pseudoephedrine, an over-the-counter oral decongestant. J Am Board Fam Pract 1992;5(5):527-528.

127. Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. South Med J 1998;91(12):1153-1155.

128. Weesner KM, Denison M, Roberts RJ. Cardiac arrhythmias in an adolescent following ingestion of an over-the-counter stimulant. Clin Pediatr (Phila) 1982;21(11):700-701.

129. Hanzlick R, Davis G. National Association of Medical Examiners Pediatric Toxicology Registry. Report 1: Phenylpropanolamine. Am J Forensic Med Pathol 1992;13(1):37-41.

130. Levisky JA, Karch SB, Bowerman DL, Jenkins WW, Johnson DG, Davies D. False-positive RIA for methamphetamine following ingestion of an ephedra-de-rived herbal product. J Anal Toxicol 2003;27:123-124.

131. Backer R, Tautman D, Lowry S, Harvey CM, Poklis A. Fatal ephedrine intoxication. J Forensic Sci 1997;42(1):157-159.

132. Levine B, Jones R, Klette K, Smith ML, Kilbane E. An intoxication involving BRON and verapamil. J Anal Toxicol 1993;17(6):381-383.

133. Baselt RC, Cravey RH, eds. Disposition of toxic drugs and chemicals in man. Foster City: Chemical Toxicology Institute, 1995.

134. Hedetoft C, Jensen CH, Christensen MR, Christensen O. [Fatal poisoning with Letigen]. Ugeskr Laeger 1999;161(50):6937-6938.

135. Blechman KM, Karch SB, Stephens BG. Demographic, pathologic, and toxico-logical profiles of 127 decedents testing positive for ephedrine alkaloids. Forensic Sci Int. 2004;139(1):61-9 as n.

136. Irvine G, Chen L, eds. The environmental impact and adverse health effects of clandestine manufacture of methamphetamine. NIDA Research Monograph 115. Miller MA, Kozel NJ, eds. N. Bethesda: National Institute on Drug Abuse, 1991, pp.33-46.

137. Dingemanse J, Guentert T, Gieschke R, Stabl M. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. J Cardiovasc Pharmacol 1996;28(6):856-861.

138. Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol (Oxf) 1995;42(1):95-98; discussion 98-99.

139. Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med 1995;12(1):49-51.

140. Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 1994;12(6):642-644.

141. Reeves RR, Pinkofsky HB. Postpartum psychosis induced by bromocriptine and pseudoephedrine. J Fam Pract 1997;45(2):164-166.

142. Inomata S, Nishikawa T, Kihara S, Akiyoshi Y. Enhancement of pressor response to intravenous phenylephrine following oral clonidine medication in awake and anaesthetized patients. Can J Anaesth 1995;42(2):119-125.

143. Tanaka M, Nishikawa T. Enhancement of pressor response to ephedrine following clonidine medication. Anaesthesia 1996;51(2):123-127.

144. Tekol Y, Tercan E, Esmaoglu A. Ephedrine enhances analgesic effect of morphine. Acta Anaesthesiol Scand 1994;38(4):396-397.

145. Walton R, Manos GH. Psychosis related to ephedra-containing herbal supplement use. South Med J 2003;96:718-720.

Chapter 2

51 Tips for Dealing with Kidney Stones

51 Tips for Dealing with Kidney Stones

Do you have kidney stones? Do you think you do, but aren’t sure? Do you get them often, and need some preventative advice? 51 Tips for Dealing with Kidney Stones can help.

Get My Free Ebook


Post a comment